KNSA Overview
Upcoming Projects (KNSA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KNSA)
-
Checking in on Arcalyst - Physician Experience with Arcalyst and its use in Recurrent Pericarditis
Ticker: KNSA
Executed On: Feb 28, 2024 at 08:00 AM EST -
A Second Opinion: Discussing the potential of Kiniksa's KPL-404 and Aclaris's zunsemetinib (ATI-450) for treatment of patients with rheumatoid arthritis
Tickers: KNSA, ACRS
Executed On: Aug 17, 2023 at 05:00 PM EDT -
Discussing the potential of Kiniksa's KPL-404 and Aclaris's zunsemetinib (ATI-450) for treatment of patients with rheumatoid arthritis
Tickers: KNSA, ACRS
Executed On: Aug 03, 2023 at 05:30 PM EDT -
A discussion of Arcalyst from Kiniksa Pharmaceuticals in recurrent pericarditis.
Ticker: KNSA
Executed On: May 30, 2023 at 02:00 PM EDT
Upcoming & Overdue Catalysts (KNSA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (KNSA)
-
Kiniksa Pharmaceuticals' (KNSA) Rilonacept in Pericarditis PDUFA date under priority review due March 21, 2021
Ticker: KNSA
Occurred on: Mar 18, 2021 -
Kiniksa (KNSA) Announces Top-Line Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
Ticker: KNSA
Occurred on: Jun 29, 2020
Strategic Initiatives (KNSA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
